Compare Applied Digital Corporation (APLD) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Applied Digital Corporation vs Citius Pharmaceuticals Inc — how do they compare? Applied Digital Corporation trades at $30.63 (market cap $8.90B), while Citius Pharmaceuticals Inc trades at $0.58 (market cap $16.00M). The key difference: Applied Digital Corporation is far larger — about 556.3× Citius Pharmaceuticals Inc's market cap, and Applied Digital Corporation is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| APLD | CTXR | |
|---|---|---|
Market Cap | $8.90B | $16.00M |
Sector | Technology | Health |
52-Week High | $49.65 | $1.82 |
52-Week Low | $9.18 | $0.53 |
Enterprise Value | $10.00B | $12.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Applied Digital (APLD) trades at $31.15, down 3.53% today, amid bearish technical signals despite unanimous analyst buy ratings. The company shows strong revenue growth with $144M in 2025 and $319M projected for 2026, but remains unprofitable with negative margins. Recent news highlights APLD's pivot to AI data centers with $36B in contracted lease value, though execution risks and customer concentration persist.
Outlook: High growth potential from AI infrastructure expansion contrasts with profitability challenges and heavy capital spending. Risks include customer concentration and debt load, but analyst consensus targets $76.67 suggest significant upside if execution improves.
CTXR trades at $0.5827, up 3.81% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported a net loss of $37.43M in 2025 with a -823.34% net margin, though revenue reached $5.6M in H1 2026 from LYMPHIR commercialization. Recent news highlights positive Phase 1 data for LYMPHIR presented at ASCO 2026.
Outlook remains speculative with high cash burn offset by financing; analyst consensus is 83% buy but financial sustainability depends on successful drug adoption. Key risks include clinical trial outcomes, dilution from recent $5M offering, and achieving profitability amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applied Digital Corporation
Applied Digital provides high-performance computing (HPC) infrastructure and cloud services. It designs and operates data centers tailored for AI, machine learning, and other intensive digital workloads across North America.
Read more on APLD →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
